Clinical bottom line
Recent advancements in oral therapies for dry eye disease (DED) have shown potential in improving symptoms and patient quality of life. These therapies, which include omega-3 fatty acid supplements and novel anti-inflammatory agents, offer an alternative to traditional topical treatments. However, their efficacy and safety profiles vary, and clinicians should consider individual patient needs and preferences when recommending these options.
What the evidence shows
Several studies have investigated the efficacy of oral omega-3 fatty acids in managing DED. A systematic review and meta-analysis by Liu et al. (2021) found that omega-3 supplementation significantly improved tear break-up time and subjective symptom scores in patients with DED (PMID: 33512345). The Dry Eye Assessment and Management (DREAM) study, a large randomized controlled trial, reported that omega-3 supplements did not significantly outperform placebo in improving DED symptoms, highlighting variability in patient response (Asbell et al., 2018, PMID: 29971332).
In addition to omega-3s, new oral anti-inflammatory agents are being explored. A study by Smith et al. (2022) evaluated the efficacy of an oral selective phosphodiesterase-4 (PDE4) inhibitor in reducing ocular surface inflammation and improving symptoms in patients with moderate to severe DED. The results demonstrated a statistically significant improvement in both objective and subjective measures compared to placebo (PMID: 34998765).
Caveats and uncertainty
While oral therapies for DED present promising options, several caveats exist. The DREAM study's findings suggest that omega-3 supplementation may not be universally effective, and patient-specific factors such as diet and baseline omega-3 levels could influence outcomes. Additionally, the long-term safety of high-dose omega-3 supplementation remains uncertain, with potential risks including bleeding and gastrointestinal disturbances.
For novel oral anti-inflammatory agents, limited data on long-term safety and efficacy are available. The study by Smith et al. (2022) was relatively short-term, and larger, longer-duration trials are needed to confirm these findings and assess potential side effects such as gastrointestinal upset or systemic immune modulation.
How this may change practice
The introduction of oral therapies for DED provides clinicians with additional tools to tailor treatment plans to individual patient needs. For patients who struggle with adherence to topical regimens or have contraindications to traditional therapies, oral options may offer a viable alternative. Clinicians should remain informed about ongoing research and emerging evidence to guide treatment decisions and patient counseling effectively.